tbuckley/cabot-search huggingface dataset:
Histone-Related Genes Are Hypermethylated in Lung Cancer and Hypermethylated <i>HIST1H4F</i> Could Serve as a Pan-Cancer Biomarker
Authors: Shihua Dong, Wei Li, Lin Wang, Jie Hu, Yuanlin Song, Baolong Zhang, Xiaoguang Ren, Shimeng Ji, Jin Li, Peng Xu, Ying Liang, Gang Chen, Jia-Tao Lou, Wenqiang Yu
Journal: Cancer Research (2019)

Lung cancer is the leading cause of cancer-related deaths worldwide. Cytologic examination is the current "gold standard" for lung cancer diagnosis, however, this has low sensitivity. Here, we identified a typical methylation signature of histone genes in lung cancer by whole-genome DNA methylation analysis, which was validated by The Cancer Genome Atlas (TCGA) lung cancer cohort (n = 907) and was further confirmed in 265 bronchoalveolar lavage fluid samples with specificity and sensitivity of 96.7% and 87.0%, respectively. More importantly, HIST1H4F was universally hypermethylated in all 17 tumor types from TCGA datasets (n = 7,344), which was further validated in nine different types of cancer (n = 243). These results demonstrate that HIST1H4F can function as a universal-cancer-only methylation (UCOM) marker, which may aid in understanding general tumorigenesis and improve screening for early cancer diagnosis. SIGNIFICANCE: These findings identify a new biomarker for cancer detection and show that hypermethylation of histone-related genes seems to persist across cancers.
Drug Rediscovery Protocol: Expanded use of existing anticancer drugs
Authors: E.E. Voest, D.L. van der Velden, L. Hoes, H. Van Der Wijngaart, M. Van Berge Henegouwen, E. Van Werkhoven, P. Roepman, A.D.R. Huitema, C. van Herpen, D.J. de Groot, L. Devriese, M.J.A. de Jonge, M. Chalabi, E.F. Smit, N. Mehra, M. Labots, S. Sleijfer, E. Cuppen, H.M.W. Verheul, H. Gelderblom
Journal: Annals of Oncology (2019)
Abstract 3349: A Flow-guided Concept To Treat Side Branches In True Bifurcation Lesions: A Randomized Clinical Study - Thueringer Bifurcation Study, THUEBIS-Study
Authors: Hubertus von Korn, Marc Ohlow, Jiangtao Yu, Burkhard Huegl, Walter Schulte, Andreas Wagner, Kai Haberl, Bernward Lauer
Journal: Circulation (2007)
Intratumoral and peripheral exploratory biomarker analysis in patients with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC) treated with RM-1929 photoimmunotherapy
Authors: J.D. Bui, N. Suslov, D. Yadav, J. Fong, E. Sun, M. Haedo, M. Garcia-Guzman
Journal: Annals of Oncology (2019)
Pembrolizumab in microsatellite instability high cancers: Updated analysis of the phase II KEYNOTE-164 and KEYNOTE-158 studies
Authors: L.A. Diaz, D. Le, M. Maio, P.A. Ascierto, R. Geva, D. Motola-Kuba, T. André, E. Van Cutsem, M. Gottfried, E. Elez, J.-P. Delord, D. Jäger, T.W. Kim, R. Guimbaud, T. Yoshino, M. Chen, K. Norwood, P. Marinello, A. Marabelle
Journal: Annals of Oncology (2019)
An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumours
Authors: C G C A Jackson, S. Deva, K. Bayston, B. McLaren, P. Barlow, N.A. Hung, K. Clarke, E. Segelov, T.-Y. Chao, M.-S. Dai, H.-T. Yen, D. Cutler, D. Kramer, J. Zhi, W.-K. Chan, M -F R Kwan, C.-T. Hung
Journal: Annals of Oncology (2019)
A prospective study of diffusion-weighted magnetic resonance imaging for predicting outcome following chemoradiotherapy, in squamous cell carcinomas of the anus
Authors: R. Muirhead, D. Bulte, R. Cook, K.-Y. Chu, L. Durrant, V. Goh, C. Jacobs, S.M. Ng, V.Y. Strauss, P.S. Virdee, C. Qi, M.A. Hawkins
Journal: Annals of Oncology (2019)
Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Authors: J Mosquera Martinez, M. Riuvadets, M.-R. García- Campelo, J Serra Lopez, G Anguera Palacios, P Gallardo Melo, I. Sullivan, A Barba Joaquin, M Majem Tarruella, C Reboredo Rendo, P Cordeiro González
Journal: Annals of Oncology (2019)

Abstract   Background  Immune-checkpoint inhibitors (ICIs) are a standard-of-care in advanced non-small cell lung cancer (NSCLC). Corticosteroids are often used in symptomatic patients, but their immunosuppressive effect may reduce the efficacy of ICIs. We report our experience in NSCLC and the potential impact of on-treatment use of corticosteroids and antibiotics.    Methods  Medical records of 267 patients with advanced NSCLC receiving ICIs from March 2013 to August 2018 were reviewed. Corticosteroid usage at the time of initiation or during ICIs treatment and administration of antibiotics from 3 months before the initiation of ICIs to 3 months after treatment end were collected. Kaplan Meier and log-rank tests were used to evaluate progression-free (PFS) and overall survival (OS). A multivariable analysis was performed to study the influence of clinical characteristics on treatment efficacy.    Results  146 patients (55%) received corticosteroids: 43% for the treatment of irAEs and 57% for the management of baseline conditions. Prednisone (40%) and dexamethasone (35%) were the most commonly used. Median dose of prednisone equivalent was 50mg daily, 92% received ≥10mg prednisone equivalent daily. Median duration of corticosteroids was 59 days. OS was longer in the group that did not receive corticosteroids or received     Conclusions  The use of ≥ 10mg of prednisone equivalent daily was associated with poorer outcomes, especially when given for baseline condition. No correlation was found between antibiotics and survival. Corticosteroids usage may identify a population with higher volume and aggressive tumors. Prudent use of corticosteroids needs to be warranted.    Legal entity responsible for the study  The authors.    Funding  Has not received any funding.    Disclosure  All authors have declared no conflicts of interest.
Abstract 19699: A Change in Cardiac Rehabilitation Referral Defaults From Opt-In to Opt-Out Increases Referral Rates Among Patients With Ischemic Heart Disease
Authors: Srinath Adusumalli, Elizabeth G Jolly, Neel P Chokshi, Lynn A Washington, Laura Suchoicki, Michelle M Walsh, Teresa Slater, Jennifer S Myers, Daniel M Kolansky, Mitesh S Patel
Journal: Circulation (2017)

Introduction: Cardiovascular disease is the leading cause of mortality globally and ischemic heart disease (IHD) is its most common manifestation. Cardiac rehabilitation (CR) reduces rates of morta...
Possible Involvement of YB-1 in Abnormal Nuclear Shape of Adult T-Cell Leukemia/Lymphoma Cell
Authors: Misaki Kakoki, Hiroo Katsuya, Paola Miyazato, Takafumi Noguchi, Yuki Inada, Misaki Matsuo, Hiroyuki Hata, Tokio Tani, Yorifumi Satou
Journal: Blood (2017)
Impact of tumor reoxygenation by nanoparticles on tumor associated macrophages (TAMs)
Authors: A.E. Ferré, C. Anfray, M.M. Leblond, H. Ozcelik, C. Helaine, S. Komaty, E. Petit, M. Bernaudin, Z. Mintova, S. Valable
Journal: Annals of Oncology (2019)
Ascites-derived circulating microRNAs as potential diagnostic biomarkers of gastric cancer-associated malignant ascites
Authors: H.S. Han, H.B. Chae, J. Yun, H.J. Kim, S.-I. Go, W.S. Lee, W.K. Bae, S.H. Cho, E.-K. Song
Journal: Annals of Oncology (2019)
Urine extracellular vesicle GATA2 mRNA alone and in a multigene test predicts initial prostate biopsy result
Authors: J. Woo, S. Santasusagna, J. Banks, A. Dominguez-Andres, K. Yadav, R. Pippa, M. Carceles-Cordon, C.D. Lallas, G. Luyao, V. Rodriguez-Bravo, A. Tewari, S. Pastor-Lopez, W.K. Kelly, B.E. Leiby, J.M. Prats, L. Gomella, J. Domingo-Domenech
Journal: Annals of Oncology (2019)
Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small cell cell lung cancer cell models
Authors: J. Codony-Servat, C. Codony-Servat, S. Viteri, M. Ito, I. Chaib, J. Bracht, M.A. Molina-Vila, N. Karachaliou, R. Rosell
Journal: Annals of Oncology (2019)
Estimating the cost and survival impact of new aNSCLC therapies in Canada with the iTEN model
Authors: P.K. Cheema, W.K. Evans, R. Burkes, R. Sangha, C. Ho, P. Wheatley-Price, D. Boehm, J. Venkatesh, S. Walisser, D. Grima, D. Moldaver, M. Hurry
Journal: Annals of Oncology (2019)
Zika Virus Infection — After the Pandemic
Authors: Didier Musso, Albert I. Ko, David Baud
Journal: New England Journal of Medicine (2019)

Zika Virus and Its Associated Diseases Zika is a mosquito-borne flavivirus that can cause congenital defects, including microcephaly. Although most Zika virus infections are asymptomatic, rash, fev...
Safety and efficacy of TRIplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [TRIDeNT] in patients (pts) with BRAF-mutated metastatic melanoma (MM): A single center phase II study
Authors: E.M. Burton, R.N. Amaria, I.C. Glitza, M. Shephard, A. Diab, D. Milton, S. Patel, J. Mcquade, M. Wong, P. Hwu, J. Wargo, M.A. Davies, H.A. Tawbi
Journal: Annals of Oncology (2019)
Clinical benefit from late lines of therapy offered to patients treated in a tertiary referral centre
Authors: A. Sbrana, F. Paolieri, E. Sammarco, F. Bloise, G. Zucchelli, V. Massa, G. Lorenzini, B. Borelli, A. Boccaccino, S. Catanese, I. Pecora, L. Galli, A. Fontana, A. Falcone, A. Antonuzzo
Journal: Annals of Oncology (2019)
Quantifying Preexisting Resistant and Persister Populations–Letter
Authors: Hitesh B. Mistry, James W.T. Yates
Journal: Cancer Research (2019)

The article by Grassberger and colleagues ([1][1]) describes how longitudinal tumor measurement data may be used to explore the debate around whether resistance to EGFR tyrosine kinase inhibitors (TKI) is acquired or preexisting in patients with cancer. The authors describe a mathematical model,
Update: Syringe-Exchange Programs—United States, 1996
Journal: JAMA (1997)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The ORCHESTRA trial; A phase III trial of adding tumour debulking to systemic therapy versus systemic therapy alone in multi-organ metastatic colorectal cancer (mCRC)
Authors: L. Bakkerus, E.C. Gootjes, E.P. van der Stok, T.E. Buffart, B.M. Zonderhuis, J.B. Tuynman, M.R. Meijerink, P.M. van de Ven, C.J. Haasbeek, A.J. Ten Tije, J.W. de Groot, S.A. Radema, M.P. Hendriks, H.H. Helgason, E. van Meerten, J.J. Nuyttens, D.J. Grünhagen, C. Verhoef, H.M.W. Verheul
Journal: Annals of Oncology (2019)
Second-line chemotherapy (SLC) in patients with advanced biliary tract and gallbladder cancers (ABGC) prolongs survival: A retrospective population-based cohort study
Authors: A. Zaidi, N. Chandna, G. Narasimhan, M. Moser, K. Haider, H.I. Chalchal, J. Shaw, S. Ahmed
Journal: Annals of Oncology (2019)
FDG PET/CT Image for a Rosai-Dorfman Disease With Pituitary and Bone Involvement in a Pediatric Patient
Authors: Ziren Kong, Yu Wang, Wenbin Ma, Xin Cheng
Journal: Clinical Nuclear Medicine (2019)

Rosai-Dorfman disease, also known as sinus histiocytosis with massive lymphadenopathy, is a rare nonneoplastic histiocytic disorder that often involves the lymph nodes and occasionally the central nervous system or skeleton. However, the presence of extranodal Rosai-Dorfman lesions without lymphadenopathy is extremely rare. Here we present a case of a pathological confirmed Rosai-Dorfman disease with pituitary and skeletal involvement without lymph nodes involvement.
Reply to ‘Strengths and limitations of estimated and measured GFR’
Authors: Esteban Porrini, Piero Ruggenenti, Sergio Luis-Lima, Fabiola Carrara, Alejandro Jiménez, Aiko P. J. de Vries, Armando Torres, Flavio Gaspari, Giuseppe Remuzzi
Journal: Nature Reviews Nephrology (2019)
Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)
Authors: N. Gross, R. Ferrarotto, P. Nagarajan, D. Bell, A. El-Naggar, J.M. Johnson, Y. Yuan, B.S. Glisson, M. Wong, D. Rosenthal, B. Esmaeli, M.R. Migden, J. Wargo, R.S. Weber, J. Myers
Journal: Annals of Oncology (2019)
An injectable heparin-Laponite hydrogel bridge FGF4 for spinal cord injury by stabilizing microtubule and improving mitochondrial function
Authors: Chenggui Wang, Zhe Gong, Xianpeng Huang, Jingkai Wang, Kaishun Xia, Liwei Ying, Jiawei Shu, Chao Yu, Xiaopeng Zhou, Fangcai Li, Chengzhen Liang, Qixin Chen
Journal: Theranostics (2019)

Rationale: Spinal cord injury (SCI) remains a critical clinical challenge. The controlled release of FGF4, a novel neuroprotective factor, from a versatile Laponite hydrogel to the injured site was a promising strategy to promote axon regeneration and motor functional recovery after SCI. Methods: Characterization of Laponite, Laponite/Heparin (Lap/Hep) and Laponite/Heparin loaded with FGF4 (Lap/Hep@FGF4) hydrogels were measured by rheometer. Multiple comprehensive evaluations were used to detect motor functional recovery and the axonal rehabilitation after Lap/Hep@FGF4 treatment in vivo (SCI rat model). Moreover, microtubule dynamic and energy transportation, which regulated axonal regeneration was evaluated by Lap/Hep@FGF4 gel in vitro (primary neuron). Results: FGF4 released from Lap/Hep gel locally achieves strong protection and regeneration after SCI. The Lap/Hep@FGF4 group revealed remarkable motor functional recovery and axonal regrowth after SCI through suppressing inflammatory reaction, increasing remyelination and reducing glial/fibrotic scars. Furthermore, the underlying mechanism of axonal rehabilitation were demonstrated via enhancing microtubule stability and regulating mitochondrial localization after Lap/Hep@FGF4 treatment. Conclusion: This promising sustained release system provides a synergistic effective approach to enhance recovery after SCI underlying a novel mechanism of axonal rehabilitation, and shows a translational prospect for the clinical treatment of SCI.
OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer: Vistusertib
Authors: S. Banerjee, L.-A. Lewsley, A.R. Clamp, J. krell, R. Herbertson, R.M. Glasspool, C. Orbegoso, C. Green, R.S. Kristeleit, C. Gourley, C. Cambell, U. Banerji, C. Shepherd, W. Brugger, L. Chudleigh, A. Hanif, I.A. McNeish, J. Paul
Journal: Annals of Oncology (2019)
Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials
Authors: R.S. Herbst, G. Lopes, D.M. Kowalski, M. Nishio, Y.-L. Wu, G. de Castro Junior, P. Baas, D.-W. Kim, M.A. Gubens, R. Cristescu, D. Aurora-Garg, A. Albright, M. Ayers, A. Loboda, J. Lunceford, J. Kobie, G.M. Lubiniecki, M.C. Pietanza, B. Piperdi, T.S.K. Mok
Journal: Annals of Oncology (2019)
Real-world implementation of sequential targeted therapies for EGFR-mutated NSCLC
Authors: P. Christopoulos, A.-L. Volckmar, F. Bozorgmehr, N. Magios, J.B. Kuon, M. Kirchner, D. Kazdal, V. Endris, T. Bochtler, F.J.F. Herth, C.-P. Heussel, H. Winter, T. Muley, M. Meister, J.R. Fischer, S. Rieken, M. Faehling, H. Bischoff, A. Stenzinger, M. Thomas
Journal: Annals of Oncology (2019)
Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial
Authors: A. Llombart Cussac, J. Medioni, M.A. Colleoni, J. Ettl, P. Schmid, I. Macpherson, J. Gligorov, J. Albanell, M. Bellet Ezquerra, A. Fernández, M. Ruiz Borrego, J. Gavilá-Gregori, D. Wheatley, P. Zamora, E. Martínez, M. Sampayo, F. Riva, A. Malfettone, J.M. Pérez-García, J. Cortés
Journal: Annals of Oncology (2019)
GLOW: Randomized phase III study of zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment of patients with CLD18.2+/HER2− locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Authors: M. Shah, J.A. Ajani, S.-E. Al-Batran, Y.-J. Bang, D.V. Catenacci, P. Enzinger, D. Ilson, S. Kim, F. Lordick, K. Shitara, E. Van Cutsem, A. Arozullah, J.W. Park, R.-H. Xu
Journal: Annals of Oncology (2019)
TP53 mutations predicts worse prognosis in EGFR-mutated NSCLC patients receiving TKIs in first- or further line of treatment
Authors: M. Canale, N. De Luigi, E. Petracci, A. Delmonte, V. Ludovini, A. Dubini, S. Baglivo, E. Minenza, E. Chiadini, L. Landi, M. Papi, G. Bronte, L. Crinò, P. Ulivi
Journal: Annals of Oncology (2019)
Evaluation of antibody-dependent cell cytotoxicity (ADCC) in lung cancer cell lines treated with combined anti-EGFR and anti-PD-L1 therapy
Authors: F. Sparano, G. Barra, C.M. Della Corte, R. Di Liello, M. Fasano, F. Ciardiello, F. Morgillo
Journal: Annals of Oncology (2019)
POLO: Health-related quality of life (HRQoL) of olaparib maintenance treatment versus placebo in patients with a germline BRCA mutation and metastatic pancreatic cancer (mPC)
Authors: P. Hammel, H.L. Kindler, M. Reni, E. Van Cutsem, T. Macarulla Mercade, M.J. Hall, J.O. Park, D. Hochhauser, D. Arnold, D.-Y. Oh, A. Reinacher-Schick, G. Tortora, H. Algül, E.M. O’Reilly, D. McGuinness, K.Y. Cui, S. Joo, H.K. Yoo, N. Patel, T. Golan
Journal: Annals of Oncology (2019)
Impact of prophylactic systemic antibiotics (SA) on outcome of patients (pts) with RAS-wildtype (RAS-wt) metastatic colorectal carcinoma (mCRC) treated with cetuximab-based first-line therapy. Subgroup analysis of the german non-interventional study ERBITAG
Authors: S.W. Sahm, M.-O. Zahn, C. Maintz, T. Goehler, J. Janssen, C. Hering-Schubert, O. Rubanov, I. Zander, K.G. Stenzel, F. Overkamp
Journal: Annals of Oncology (2019)
Current practices for respiratory syncytial virus surveillance across the EU/EEA Member States, 2017
Authors: Madelief Mollers, Céline Barnadas, Eeva K Broberg, Pasi Penttinen, Anne C Teirlinck, Thea K Fischer
Journal: Eurosurveillance (2019)

BackgroundRespiratory syncytial virus (RSV) is a major contributor to lower respiratory tract infections worldwide and several vaccine candidates are currently in development. Following vaccine introduction, reliable RSV surveillance should enable monitoring of vaccination impact. Data on the RSV disease burden in the European Union and European Economic Area (EU/EEA) are sparse.AimThe aim of this study was to gather knowledge on current practices of national RSV surveillance in the EU/EEA.MethodsNational Coordinators and National Focal Points for Influenza (epidemiologists and virologists) from the EU/EEA countries (n = 31) were invited to participate in an online survey in August and September 2017. The questionnaire covered questions on epidemiological and laboratory aspects of RSV surveillance.ResultsAll EU/EEA countries except Liechtenstein replied to the survey. Eighteen countries reported to have a sentinel surveillance system, 26 countries a non-sentinel surveillance system and three countries to have neither. RSV data collection was mostly done within the context of influenza surveillance. A wide range of diagnostic and characterisation assays was used for the detection of RSV.DiscussionThe majority of EU/EEA countries have some surveillance for RSV in place. The prevailing integration of RSV surveillance into the existing influenza sentinel surveillance system may lead to under-reporting of RSV. The documented variations in existing RSV surveillance systems and their outputs indicate that there is scope for developing guidelines on establishing comparable methods and outcomes for RSV surveillance across the EU/EEA, to ensure the availability of a consistent evidence base for assessing future vaccination programmes.
A phase II study of monalizumab in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN): Results of the I1 cohort of the EORTC-HNCG-1559 trial (UPSTREAM)
Authors: R. Galot, C. Le Tourneau, E. Saada-Bouzid, A. Daste, C. Even, P.R. Debruyne, S. Henry, S. Zanetta, A. Rutten, L.F. Licitra, J.-L. Canon, M.-C. Kaminsky-Forrett, P. Specenier, S. Rottey, L. Dirix, T. Raveloarivahy, C. Fortpied Lefevre, M.B.M. Vanlancker, A.-S. Govaerts, J.-P. Machiels
Journal: Annals of Oncology (2019)
Immune-Related Adverse Events of Immune Checkpoint Inhibitors—From a Clinical to Pathophysiological View—In Reply
Authors: Fiamma Berner, David Bomze, Lukas Flatz
Journal: JAMA Oncology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Redefining the IGCCCG classification in advanced non-seminoma
Authors: S. Gillessen, L. Collette, G. Daugaard, R. de Wit, A. Tryakin, C. Albany, O. Stahl, K. Fizazi, J.A. Gietema, U.F.F. De Giorgi, A.R. Hansen, D. Feldman, F. Cafferty, T. Tandstad, X. Garcia del Muro, R.A. Huddart, C.J. Sweeney, D.Y.C. Heng, N. Sauve, J. Beyer
Journal: Annals of Oncology (2019)